Sexual dysfunction is a well-known adverse event after transplant; however, is under-recognized and under-treated. We will review barriers to discussions surrounding sexual health after transplant as well as strategies to approach this and the role of a dedicated sexual health clinic.

Moderator: Areej El-Jawahri, MD, Massachusetts General Hospital

Speakers: 

Julie Vanderklish, NP, Harvard University

Anna Cat Morris, PA-C, Advocate Health

Join us on Tuesday, September 30 at 11 a.m. CT / 12 p.m. ET for the webinar, “The Role of RFIs in the Payer-Provider Relationship.”

This session will demystify the role of the Request for Information (RFI) in Center of Excellence (COE) participation. As we prepare for upcoming changes in 2026, the webinar will provide clarity on the purpose and evolving standards of the RFI, its connection to payer-provider relationships, and its integration with CIBMTR data.

Our speakers will discuss:

• The intent behind RFI standardization and its impact on COE participation
• Key updates to the current RFI and what to expect in 2026
• How to navigate RFI documents, source and validate data, and address common challenges
• Strategies for handling unique or emerging therapies that may not fit standard definitions

This webinar is intended for data coordinators, program managers, and anyone involved in RFI completion, but is open to all ASTCT members and non-members.

Speakers:

• Claire White, MSN, RN - Access & Policy Specialist, Children's Hospital of Philadelphia
• Victoria Collier, RN, BSN - Quality Program Manager, Children's Hospital of Philadelphia

The ASTCT Pharmacy SIG September 2025 Journal Club will air on Wednesday, September 24 at 2 p.m. CT/3 p.m. ET. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the September Journal Club session, Drs. Yi and Trinh will present two articles related to:

• Enhanced CAR T-cell therapy for lymphoma after previous failure
• Linvoseltamab for the treatment of relapsed/refractory multiple myeloma 

Presenters & Articles:

Ha Nguyen Trinh, PharmD

PGY-2 Pharmacy Resident

Emory Healthcare | Winship Cancer Institute 

Article: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure

Hannah Yi, PharmD

PGY-2 Pharmacy Resident

UT Southwestern Medical Center

Article: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review the four commercially available anti-CD19 CAR T-cell products and their place in current guideline of CD19+ B-cell lymphomas
• Evaluate the safety and efficacy of the enhanced CART T-cell therapy (huCART19-IL18) in phase 1 trial
• Discuss the clinical implications of huCART19-IL18 for relapsed CD19+ B-cell lymphomas after prior anti-CD19 CAR T-cell therapy
• Describe the current treatment landscape of relapsed/refractory multiple myeloma (RRMM)
• Analyze the efficacy outcomes and safety profile of linvoseltamab in the LINKER-MM1 trial
• Evaluate the potential clinical impact of linvoseltamab in the treatment of RRMM

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session can be found HERE. 

This interactive webinar will highlight key research abstracts featured at the 2025 Tandem Meetings of ASTCT and CIBMTR. It features posters that were selected for the Palliative Care SIG Poster Walk and emphasizes these interprofessional authors and their research posters:

Richard Newcomb, MD, Massachusetts General Hospital

• "Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation" 

Daniel Trotier, MD, The Ohio State University

• “Has Palliative Care and Hospice Utilization Changed for Patients with Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR-T?"

Alexi Vasbinder, PhD, RN, University of Washington School of Nursing

• "Associations between Symptom Severity and Distress with Functional Status after Allogeneic Hematopoietic Cell Transplantation."

This webinar discusses the role of non-Aspergillus mold infections (NAIMIs) in hematopoietic cell transplantation (HCT) recipients. Upon completion of this activity, attendees will gain knowledge on identifying NAIMIs, understanding risk factors, and recognizing clinical presentations. The session covers current diagnostic methods, treatment options, and preventive strategies, including antifungal prophylaxis and infection control measures. Participants will also learn about emerging therapies and the impact of these infections on patient outcomes.

Presenter: 

Abby P. Douglas, Department of Infectious Diseases, National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Host: Sanjeet Dadwal, MD, Professor of Medicine and Chief, Division of Infectious Disease, City of Hope National Medical Center, Los Angeles, California

The Pharmacy HCT Core Topics Live Session will air on Wednesday, September 3 from 2:00 - 3:00 p.m. CDT. This live session will focus on two core topics in the field - Conditioning Regimens & Immunosuppression Management. The faculty below will briefly present slides on their topic, and then answer questions and share their experiences from their institutions. The target audience is PGY2 Oncology Pharmacy Residents, but is open to all trainees or other practitioners interested in HCT and cellular therapy. This webinar will be recorded and there is no CE offered for attending this session.

Live Session Faculty:

Conditioning Regimens

Binni Kunvarjee, PharmD, BCOP

Clinical Pharmacy Specialist

Memorial Sloan Kettering Cancer Center

Jessica Lewis-Gonzalez, PharmD, BCOP

Oncology Clinical Pharmacy Specialist

The University of New Mexico

Immunosuppression Management

Elizabeth Eubanks, PharmD, MPH, BCPS, BCOP, CPP

Clinical Oncology Pharmacist, Adult Bone Marrow Transplant & Cellular Therapy

Duke University Medical Center

Vinita Pai, PharmD, MS, BCPPS

Associate Professor - Clinical 

College of Pharmacy, Division of Pharmacy Practice and Sciences

The Ohio State University

Join the APP SIG on Thursday, August 28 at 2 p.m. CDT for the Strategies for Difficult Conversations webinar. Providers caring for patients receiving transplants and cellular therapy are often required to deliver a range of serious news. This may include information about complications of therapy, changes to the underlying disease status, and notification that disease-directed interventions are no longer available. Attendees of this presentation will review the current literature related to communication with patients and families and discuss common practices and barriers observed. Strategies for effective communication where honest news is delivered with compassion will be described. There will be an opportunity to utilize these new skills by practicing delivering serious news guided by one of the strategies discussed.

This webinar is open to all ASTCT members and non-members. There will not be any continuing education offered for attending this webinar.

Speaker:

Jessica Spruit, DNP; University of Michigan

Join ASTCT Director of Government Relations, Molly Ford, and Reimbursement and Policy Advisors from Nimitt Consulting for a webinar on Medicare rule updates on August 20 at 12 p.m. CDT/1 p.m. EDT.

This webinar will cover:

• FY 2026 Inpatient Prospective Payment System (IPPS) Final Rule:
  • Final payment rates and policies for key MS-DRGs for Stem Cell Transplant MS-DRGs (014, 016 and 017) and CAR-T and Other Immunotherapies (MS-DRG 018)
  • Discussion of CMS’ final decisions on relevant New Technology Add-on Payments (NTAP) for cell and gene therapy products
  • Final fixed outlier loss threshold and market basket update amounts
• CY 2026 Outpatient Prospective Payment System (OPPS) Proposed Rule:
  • Major payment and policy proposals related to cell and gene therapies
  • Other major proposals likely to impact hospitals if finalized
• CY 2026 Medicare Physician Fee Schedule (MPFS) Proposed Rule:
  • Major payment and policy proposals related to cell and gene therapies
  • Other major proposals including new codes and payment rates applicable to ASTCT member physicians

There will be a Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar to info@astct.org. If you are unable to join, the recording will be made available. 

Please consider sharing this webinar with your network of doctors, administrators, providers, or any other colleagues that may be interested.

Join us for an informational webinar on Tuesday, August 12, that will highlight the major updates to the ASTCT HCT Coverage & Reimbursement Guide. This session will provide valuable insights for professionals involved in the financial authorization process for stem cell transplant process, with key topics including:

• Overview of insurance types and benefit screening
• Contracting and authorization workflows
• Registration and billing procedures for stem cell transplant cases

This webinar is free to ASTCT members and non-members. It is especially targeted toward financial specialists, coordinators, or administrators new to their roles within stem cell transplant programs. It will also be recorded for on-demand viewing. To access the HCT Coverage & Reimbursement Guide, please click HERE.

The 2025 Fundamentals of HCT eBook offers up-to-date clinical information covering the full transplant journey—from pre-transplant consultation to post-transplant care. With 32 focused chapters, this resource includes essential topics such as:

• Introduction to Transplantation

• Indications for HCT in ALL, AML, MDS, MF, Lymphoma, Multiple Myeloma, CML and CLL

• IEC Products and Indications

• IEC Toxicity Management

• Stem Cell Mobilization

• Acute and Chronic GVHD

• Vaccinations in HCT and Cellular Therapy

• Long-term Follow-up and Survivorship

• Special Populations in HCT: Pediatrics

• *New in the 2025 edition* - Special Populations in HCT: Geriatrics

• And more!

Designed for healthcare professionals, this eBook is a go-to guide for anyone involved in HCT or cellular therapy. For the best user experience and functionality, we recommend downloading the eBook and using a PDF reader like Adobe Acrobat. This eBook is licensed for use solely by the individual who purchased it. Unauthorized copying, sharing, or distribution is strictly prohibited.

ISBN: 979-8-218-74001-6